

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: **Paul HABERMANN et al.**Application No./Patent No./Control No.: **10/076,632** Filed/Issue Date: **February 19, 2002**Entitled: **Use of fusion proteins whose N-terminal part is a hirudin derivative for the production of recombinant proteins via secretion by yeasts****Sanofi-Aventis Deutschland GmbH**, a **corporation**
(Name of Assignee) (Type of Assignee: corporation, partnership, university, government agency, etc.)

States that it is:

1. The assignee of the entire right, title, and interest; or
 2. an assignee of less than the entire right, title and interest.
 The extent (by, percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____, Frame _____ or for which a copy thereof is attached.

OR


B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Inventors To: Aventis Pharma Deutschland GmbH
 The document was recorded in the United States Patent and Trademark Office at
 Reel 012882 Frame 0467 or for which a copy thereof is attached.
2. From: Aventis Pharma Deutschland GmbH To: Sanofi-Aventis Deutschland GmbH
 The document was recorded in the United States Patent and Trademark Office at
 Reel 016793 Frame 0789 or for which a copy thereof is attached.
3. From: _____ To: _____
 The document was recorded in the United States Patent and Trademark Office at
 Reel _____ Frame _____ or for which a copy thereof is attached.

 Additional documents in the chain of title are listed on a supplemental sheet. As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302.8

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Sanofi-Aventis Deutschland GmbH

Signatures

18 NOV. 2008

Date

Dr. Elmar-Michael Wein**Dieter Breuer****+49 69 305 6285**

Typed or printed names

Telephone Number

Prokurist**Authorized Signatory**

Titles

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.